How to buy MaxCyte stock

MaxCyte is a medical devices business based in the US. MaxCyte shares (MXCT) are listed on the NASDAQ and all prices are listed in US Dollars. MaxCyte employs 84 staff and has a trailing 12-month revenue of around $42 million.

MaxCyte stock price (NASDAQ: MXCT)

Use our graph to track the performance of MXCT stocks over time.

MaxCyte shares at a glance

• Key figures

Information last updated 2023-01-22.

Latest market close	$5.77
52-week range	$3.36 - $7.76
50-day moving average more info button	$5.68
200-day moving average more info button	$5.52
Wall St. target price	$11.67
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-0.17

Buy MaxCyte stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy MaxCyte stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

MaxCyte price performance over time

Historical closes compared with the close of $5.77 from 2023-01-27

1 week (2023-01-20)	8.26%
1 month (2022-12-28)	16.57%
3 months (2022-10-28)	-17.69%
6 months (2022-07-28)	5.68%

1 year (2022-01-28)	-4.63%
2 years (2021-01-24)	N/A
3 years (2020-01-24)	N/A
5 years (2018-01-24)	N/A

MaxCyte financials

Revenue TTM	$42 million
Gross profit TTM	$30.2 million
Return on assets TTM	-5.66%
Return on equity TTM	-9.12%
Profit margin	-56.29%
Book value	$2.50
Market capitalisation more info button	$566.9 million

TTM: trailing 12 months

MaxCyte share dividends

We're not expecting MaxCyte to pay a dividend over the next 12 months.

MaxCyte share price volatility

Over the last 12 months, MaxCyte's shares have ranged in value from as little as $3.36 up to $7.76. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while MaxCyte's is 0.7024. This would suggest that MaxCyte's shares are less volatile than average (for this exchange).

To put MaxCyte's beta into context you can compare it against those of similar companies.

• Sqz Biotechnologies Co (SQZ.US): 2.7798
• Onconova Therapeutics (ONTX.US): 1.5347
• Cleveland BioLabs (CBLI.US): 0.6837

MaxCyte overview

MaxCyte, Inc. , a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland. .

Frequently asked questions

What percentage of MaxCyte is owned by insiders or institutions?
Currently 1.246% of MaxCyte shares are held by insiders and 78.76% by institutions. How many people work for MaxCyte?
Latest data suggests 84 work at MaxCyte. When does the fiscal year end for MaxCyte?
MaxCyte's fiscal year ends in December. Where is MaxCyte based?
MaxCyte's address is: 9713 Key West Avenue, Rockville, MD, United States, 20850 What is MaxCyte's ISIN number?
MaxCyte's international securities identification number is: US57777K1060